Liver Transplant in India FAQ 2026: Top Questions Answered by India's Leading Specialists

Living donor liver transplant (LDLT): USD 30,000-50,000. Deceased donor (DDLT): USD 25,000-40,000. Pediatric liver transplant: USD 25,000-45,000. Combined liver-kidney: USD 45,000-65,000. All prices include pre-transplant workup, surgeon fees, anesthesia, ICU, hospital stay (3-6 weeks), immunosuppressants (1 year), and 1-year follow-up.

1-year survival for living donor liver transplant in India: 90-95% (adult), 92-96% (pediatric). 5-year survival: 80-85% (adult), 85-90% (pediatric). India's top liver transplant centers (Medanta, Apollo, Global, MIOT) match Western outcomes (UNOS registry comparisons).

Indications: end-stage liver disease (decompensated cirrhosis, MELD > 15), acute liver failure, hepatocellular carcinoma (Milan criteria), biliary atresia (pediatric), metabolic liver disease, primary biliary cirrhosis. Patients must have no active cancer, infection, or substance abuse. Comprehensive workup includes CT/MRI, liver biopsy, cardiac and pulmonary clearance.

Eligible donor: aged 18-55, blood-type compatible, BMI < 32, no chronic disease, no fatty liver (liver biopsy if BMI > 28), willing and psychologically cleared. Donor's remaining liver regenerates to 80-90% of original size within 4-6 weeks. Donor mortality risk < 0.5% in experienced centers.

Standard post-transplant stay in India: 5-8 weeks. ICU 5-7 days, ward 7-10 days, 4-6 weeks of nearby monitoring, then flight clearance. Patients should be near the transplant center for 4-6 weeks to monitor for rejection, infection, and biliary complications. Travel clearance at 6-8 weeks.

Standard triple regimen: tacrolimus (Prograf) + mycophenolate mofetil (CellCept) + prednisone (tapered off at 6 months). Tacrolimus level monitoring every 2 weeks initially, then monthly. Cost USD 200-500/month. Long-term: many patients transition to tacrolimus monotherapy at 12-24 months.

Early risks (first 30 days): rejection (10-15%), biliary complications (5-10%), infection (10-20%), bleeding (1-3%), primary non-function (< 1%). Late risks: chronic rejection (5%), recurrence of original disease (HBV/HCV), metabolic complications (diabetes, hypertension, kidney dysfunction). Survival rates justify transplantation in eligible patients.

Yes — GCC living donors are accepted. The donor travels with the patient, workup parallel, both operated within 24 hours. Donor requirements: eligible per Indian transplant act (Transplantation of Human Organs and Tissues Act 2014) — informed consent, compatibility, no commercial transaction. GCC donors need medical visa + Indian embassy attestation.

Pediatric LDLT is a major strength of Indian centers (Medanta, Apollo, Global, KIMS). Biliary atresia is the most common indication; outcomes 92-96% 1-year survival. Cost USD 25,000-45,000 (vs USD 200,000-500,000 in the USA). Living parent donors are typical. Children usually return home within 6-8 weeks.

Liver function tests (LFTs) every 1-2 weeks for first 6 months, then monthly. Tacrolimus trough levels every 2 weeks initially, then monthly. Liver biopsy only if LFTs deteriorate. Acute rejection (10-15% in first 6 months) is usually steroid-responsive (90%+ respond).

Pre-transplant: complete all standard vaccinations (especially HBV, HAV, pneumococcal, influenza, COVID-19). Live vaccines (MMR, varicella, oral polio) are CONTRAINDICATED post-transplant. Patients should be up-to-date on all vaccines 4+ weeks before transplant. Pediatric transplant patients need full catch-up immunization.

Indications: combined liver failure and ESRD, polycystic liver/kidney disease, primary hyperoxaluria. Cost USD 45,000-65,000 in India. Outcomes: 1-year survival 85-90%. Performed at major transplant centers (Medanta, Apollo, Global).

Check: (a) JCI/NABH accreditation, (b) annual liver transplant volume > 100 (high volume), (c) 1-year survival rates published, (d) dedicated transplant ICU, (e) multi-disciplinary transplant team (hepatologist, surgeon, anesthesiologist, intensivist, infectious disease, dietitian), (f) 24/7 transplant coordinator.

Hospital stay: 3-4 weeks. Full recovery with normal activity: 3-6 months. Lifelong immunosuppression, frequent blood work, and follow-up at 1, 3, 6, 12 months and annually thereafter. Most patients return to normal life (work, exercise, travel) within 6-12 months.

Tele-consults at 1, 3, 6, 12 months post-discharge, shared with the patient's local hepatologist or GP. Tacrolimus level monitoring by patient locally; results uploaded to hospital portal. Hospitals arrange prescription refills (6-12 months at a time) shipped via courier or partner pharmacies. Annual review visit optional.

Yes — donor mortality risk < 0.5% in experienced centers. Donor workup ensures fit liver. Donor hospital stay 5-7 days, recovery 6-8 weeks. Liver regenerates to 80-90% of original size within 4-6 weeks. Donors receive lifelong medical follow-up at the transplant center.

All donor livers (living or deceased) undergo: blood-type matching, crossmatch, hepatitis B/C/HIV serology, liver biopsy (if indicated), CT volumetry (for living donor right-lobe grafts), intraoperative ultrasound and biopsy. India's transplant registry (NOTTO) maintains national donor/recipient data.